All News

The expert in multiple myeloma spoke about the research that she believes will be most influential for patients with multiple myeloma.

The FDA granted approval to the combination use of cabozantinib plus nivolumab ahead of its February PDUFA date as therapy for the first-line treatment of patients with advanced renal cell carcinoma.

Findings from a phase 1/2 trial indicate that lisocabtagene maraleucel plus ibrutinib may represent a viable treatment option for patients with heavily pretreated chronic lymphocytic leukemia or small lymphocytic lymphoma and high-risk disease features.

Research published in JAMA Network Open found that total neoadjuvant therapy enhanced pathological complete response rates for patients with locally advanced rectal cancer.

The BLA submission is based on data observed in the phase 2 POD1UM-202 trial of retifanlimab in previously treated patients with locally advanced or metastatic squamous cell carcinoma of the anal canal who had progressed on, or were intolerant of, standard platinum-based chemotherapy.

The novel viral immunotherapy PVSRIPO is designed to stimulate a patient’s innate and adaptive immune system to promote an antitumor response and establish long-term immunologic memory to help keep their cancer at bay.

“Our results suggest that low [intertumoral heterogeneity] is associated with increased response to anti–PD-1 immunotherapy in renal cell carcinoma through increased immune activity involving more neoantigens and less frequent immune evasion,” wrote the study authors, led by Xia Ran.

The leukemia expert talks about how current findings may hold promise for a larger group of patients in the future.

Compared with previous standard-of-care therapy with sorafenib, the IMbrave150 combination maintains overall survival superiority in treatment-naive advanced hepatocellular carcinoma.

Encouraging efficacy and safety outcomes were reported at the 2021 Gastrointestinal Cancers Symposium when infigratinib was used to treat FGFR2 fusion–positive cholangiocarcinomas that are refractory to chemotherapy.

Thought leader detailed the findings from an oral presentation investigating patients with relapsed or refractory diffuse large B-cell lymphoma.

Overall survival benefits were noted when ivosidenib tablets were used in previously treated patients with IDH1-mutant cholangiocarcinoma when compared against placebo, according to a phase 3 trial.

The expert in multiple myeloma highlighted the research which she was most excited to see presented at the ASH Annual Meeting & Exposition.

The Breast Cancer Index assay is the only of its kind to be recommended in the National Comprehensive Cancer Network Guidelines for the treatment of breast cancer as being predictive of extended adjuvant endocrine therapy.

The ongoing phase 3 CASPIAN trial evaluating the use of intravenous durvalumab, with or without tremelimumab, added to platinum–etoposide for the first-line treatment of extensive-stage small cell lung cancer demonstrated improved overall survival versus chemotherapy alone.

Investigators aimed to evaluate additional end points from the phase 3 RxPONDER trial in women with hormone receptor–positive, HER2-negative, lymph node–positive breast cancer.

Bristol Myers Squibb announced that nivolumab has been granted priority review for indications in both the first-line and adjuvant treatment settings as therapy for gastrointestinal cancers.

The assistant professor of Urology at The University of Texas MD Anderson Cancer Center spoke about the results of a study which evaluated the use of the Mediterranean diet in men with localized prostate cancer on active surveillance.

No significant benefits to progression-free survival were noted with the axitinib-plus-octreotide combination for the treatment of patients with advanced G1-2 extra-pancreatic neuroendocrine tumors.

Data published in The Lancet found a favorable tolerability profile for the subcutaneous formulation of bortezomib when compared with previous trials of the combination panobinostat plus dexamethasone and intravenous bortezomib in myeloma.

Based on recent study results, investigators recommended TBI plus etoposide for patients older than 4 years of age with high-risk ALL undergoing allogeneic hematopoietic stem cell transplantation.

The latest episode of CancerNetwork®’s podcast examines a review article focusing on spinal metastases and stereotactic body radiation therapy.

In this trial, investigators launched RxPONDER, in which 5015 patients with a recurrence score between 0 and 25 were randomized to endocrine therapy alone or chemotherapy followed by endocrine therapy.

Overall self-reported quality of life in patients with metastatic pancreatic cancer was correlated with their mean daily step count during the first 2 weeks of treatment on SM-88.

Overall and progression-free survival with second-line pembrolizumab for hepatocellular carcinoma maintained numerical superiority, according to a phase 3 trial.

Results of a phase 2 trial presented at the 2021 ASCO Gastrointestinal Cancers Symposium show promise for immunotherapy treatment involving pembrolizumab in patients with HCC receiving no prior systemic therapy.

The phase 1b/2 trial evaluated a single, low-dose infusion of ciltacabtagene autoleucel (cilta-cel; JNJ-68284528) in heavily pretreated patients with relapsed or refractory multiple myeloma.

Data presented at the 2021 Gastrointestinal Cancers Symposium shows promise for the combination of camrelizumab plus apatinib for previously treated patients with esophageal squamous cell carcinoma.

Statistically significant improvements in PFS were seen with the multitarget kinase inhibitor anlotinib in Chinese patients with refractory metastatic colorectal cancer, with OS differences noted in certain subgroups.

Lenvatinib monotherapy was an effective first-line therapy for patients with unresectable hepatocellular carcinoma, according to data from a retrospective, real-world analysis.